Stocktoria
IDEXX LABORATORIES INC /DE IDXX
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1991-06-21
IDEXX LABORATORIES INC /DE statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% |
| Operating margin | 31.6% | 29.0% | 30.0% | 26.7% | 29.0% |
| Net margin | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% |
| FCF margin | 24.6% | 20.7% | 21.1% | 11.7% | 19.8% |
| Return on assets | 31.6% | 27.0% | 25.9% | 24.7% | 30.6% |
| Return on equity | 66.0% | 55.7% | 56.9% | 111.6% | 107.9% |
| Debt / equity | 0.28× | 0.39× | 0.47× | 1.26× | 1.23× |
| Current ratio | 1.23 | 1.31 | 1.57 | 0.89 | 1.25 |
| Revenue growth | 10.4% | 6.5% | 8.7% | 4.7% | 18.8% |
Source: SEC EDGAR filings · CIK 0000874716 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.